Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.

This study has been completed.
Sponsor:
Collaborator:
Acorda Therapeutics
Information provided by (Responsible Party):
Biogen Idec
ClinicalTrials.gov Identifier:
NCT01235221
First received: November 4, 2010
Last updated: July 3, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2012
  Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)